Enterprise Value

-22.23M

Cash

139.3M

Avg Qtr Burn

-29.72M

Short % of Float

4.94%

Insider Ownership

2.41%

Institutional Own.

93.03%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AK006 (IV) Details
Chronic spontaneous urticaria

Phase 1

Data readout

AK006 (SC) Details
Chronic spontaneous urticaria

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Lirentelimab (AK002) (Siglec-8) Details
Eosinophilic Duodentitis , Eosinophilic Gastritis

Failed

Discontinued